2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023
No.41
“A Phase 2 study of BMS-986036 (Pegylated FGF21) in Obese Adults with Type 2 Diabetes and a High Prevalence of Fatty Liver” Bristol-Myers Squibb Company
No.40
“Effects of BMS-986036 (pegylated fibroblast growth factor 21) on hepatic steatosis and fibrosis in a mouse model of nonalcoholic steatohepatitis” Bristol-Myers Squibb Company.
No.39
“Inhibition of the Ileal Bile Acid Transporter (IBAT) by A4250 Reduces Hepatic Damage in a Mouse Model of Non-Alcoholic Steatohepatitis (NASH)”Albireo AB
No.38
“DPP4 Inhibitor Suppresses Steatohepatitis and HCC Progression with Glucose Re-Programing in a Mouse Model of NASH” Kurume University School of Medicine